First Patient Dosed in SANTANA-225 Ph 1/2 Trial of 225Ac-SSO110 in Patients with ES-SCLC or MCC
“RLTs are redefining precision oncology by enabling targeted delivery of radiation directly to tumor cells while minimizing exposure to healthy tissue,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “225Ac-SSO110 is the first SSTR2 antagonist RLT in clinical development, designed to deliver higher doses of alpha radiation directly to patients’ tumors while maintaining a favorable safety profile for individuals with neuroendocrine cancers, including ES-SCLC and MCC. Dosing the first patient in the SANTANA-225 trial is a significant step for our lead program and an important milestone towards addressing urgent patient needs in these aggressive cancers. We expect to report initial safety data from the SANTANA-225 trial in 2026, which may support expansion into additional neuroendocrine tumor indications and further validate the differentiated mechanism of action of 225Ac-SSO110.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a